LivaNova (NASDAQ:LIVN) Raised to Outperform at Robert W. Baird

LivaNova (NASDAQ:LIVN) was upgraded by stock analysts at Robert W. Baird from a “neutral” rating to an “outperform” rating in a report released on Tuesday, Benzinga reports. The brokerage currently has a $66.00 target price on the stock, up from their prior target price of $55.00. Robert W. Baird’s price objective would indicate a potential upside of 35.27% from the company’s current price.

A number of other equities analysts also recently issued reports on LIVN. Needham & Company LLC increased their target price on LivaNova from $72.00 to $75.00 and gave the stock a “buy” rating in a research note on Wednesday, July 31st. Stifel Nicolaus increased their price objective on LivaNova from $70.00 to $72.00 and gave the stock a “buy” rating in a research report on Thursday, July 25th. One investment analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. According to data from MarketBeat, LivaNova presently has an average rating of “Moderate Buy” and an average target price of $70.80.

LivaNova Stock Performance

NASDAQ:LIVN opened at $48.79 on Tuesday. The company has a debt-to-equity ratio of 0.49, a current ratio of 3.45 and a quick ratio of 2.94. The firm has a market cap of $2.65 billion, a price-to-earnings ratio of -81.32 and a beta of 1.00. The firm’s fifty day moving average price is $48.85 and its 200 day moving average price is $53.47. LivaNova has a 1-year low of $42.75 and a 1-year high of $64.47.

LivaNova (NASDAQ:LIVN) last issued its earnings results on Wednesday, July 31st. The company reported $0.81 earnings per share for the quarter, beating the consensus estimate of $0.66 by $0.15. The business had revenue of $318.60 million for the quarter, compared to the consensus estimate of $305.05 million. LivaNova had a negative net margin of 1.37% and a positive return on equity of 13.77%. On average, sell-side analysts expect that LivaNova will post 2.58 EPS for the current year.

Hedge Funds Weigh In On LivaNova

Several hedge funds have recently bought and sold shares of the company. Fifth Third Bancorp grew its holdings in LivaNova by 97.1% in the second quarter. Fifth Third Bancorp now owns 674 shares of the company’s stock valued at $37,000 after purchasing an additional 332 shares during the last quarter. Hexagon Capital Partners LLC boosted its position in shares of LivaNova by 117.8% in the 2nd quarter. Hexagon Capital Partners LLC now owns 684 shares of the company’s stock worth $37,000 after buying an additional 370 shares in the last quarter. Lazard Asset Management LLC acquired a new stake in LivaNova in the 1st quarter valued at about $84,000. Canada Pension Plan Investment Board acquired a new stake in LivaNova in the 2nd quarter valued at about $88,000. Finally, Acadian Asset Management LLC purchased a new position in LivaNova during the 1st quarter valued at about $94,000. 97.64% of the stock is owned by hedge funds and other institutional investors.

LivaNova Company Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.